Sentynl Therapeutics, Inc.
Clinical trials sponsored by Sentynl Therapeutics, Inc., explained in plain language.
-
New hope for kids with rare copper deficiency disease
Disease control APPROVED_FOR_MARKETINGThis program gives children under 6 with Menkes disease access to copper histidinate injections. Menkes disease is a rare genetic disorder where the body cannot properly use copper, leading to severe developmental problems. The treatment aims to supply the missing copper to help …
Sponsor: Sentynl Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Researchers track menkes disease over time to unlock key insights
Knowledge-focused OngoingThis study gathers long-term health information from up to 50 people with Menkes disease, a rare genetic disorder. The goal is to track survival and nervous system changes over time. No new treatments are being tested; instead, researchers are collecting data to better understand…
Sponsor: Sentynl Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC